These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22819584)

  • 1. Diffusion-weighted imaging of local recurrent prostate cancer after radiation therapy: comparison with 22-core three-dimensional prostate mapping biopsy.
    Hara T; Inoue Y; Satoh T; Ishiyama H; Sakamoto S; Woodhams R; Baba S; Hayakawa K
    Magn Reson Imaging; 2012 Oct; 30(8):1091-8. PubMed ID: 22819584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.
    Kim CK; Park BK; Lee HM
    J Magn Reson Imaging; 2009 Feb; 29(2):391-7. PubMed ID: 19161194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience.
    Kim CK; Park BK; Park W; Kim SS
    Abdom Imaging; 2010 Apr; 35(2):246-52. PubMed ID: 19130116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors.
    Tamada T; Sone T; Jo Y; Hiratsuka J; Higaki A; Higashi H; Ito K
    AJR Am J Roentgenol; 2011 Aug; 197(2):408-14. PubMed ID: 21785087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of diffusion-weighted imaging in the localization of prostate cancer.
    Kajihara H; Hayashida Y; Murakami R; Katahira K; Nishimura R; Hamada Y; Kitani K; Kitaoka M; Suzuki Y; Kitajima M; Hirai T; Morishita S; Awai K; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):399-403. PubMed ID: 19019564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.
    Roy C; Foudi F; Charton J; Jung M; Lang H; Saussine C; Jacqmin D
    AJR Am J Roentgenol; 2013 Apr; 200(4):W361-8. PubMed ID: 23521479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies.
    Rud E; Baco E; Lien D; Klotz D; Eggesbø HB
    AJR Am J Roentgenol; 2014 Mar; 202(3):W241-6. PubMed ID: 24555620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization.
    Rosenkrantz AB; Mannelli L; Kong X; Niver BE; Berkman DS; Babb JS; Melamed J; Taneja SS
    J Magn Reson Imaging; 2011 Jul; 34(1):95-100. PubMed ID: 21698707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
    Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
    J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer: application in patient selection for hemiablative focal therapy.
    Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
    Eur Urol; 2014 Jan; 65(1):186-92. PubMed ID: 23084330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system.
    Quentin M; Arsov C; Röhlen S; Klasen J; Antoch G; Albers P; Blondin D
    Rofo; 2012 Oct; 184(10):925-9. PubMed ID: 22744328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical value of 3 tesla diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer].
    Shimamoto T; Ashida S; Yamasaki I; Kuno T; Fukuhara H; Fukata S; Satake H; Tamura K; Karashima T; Kamata M; Inoue K; Shuin T; Kariya S; Ogawa Y
    Hinyokika Kiyo; 2012 Mar; 58(3):143-8. PubMed ID: 22495042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy.
    Yamamura J; Salomon G; Buchert R; Hohenstein A; Graessner J; Huland H; Graefen M; Adam G; Wedegaertner U
    J Comput Assist Tomogr; 2011; 35(2):223-8. PubMed ID: 21412094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental value of T2-weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized prostate cancer.
    Nishida K; Yuen S; Kamoi K; Yamada K; Akazawa K; Ito H; Okihara K; Kawauchi A; Miki T; Nishimura T
    Acta Radiol; 2011 Feb; 52(1):120-6. PubMed ID: 21498337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
    J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of locally recurrent pelvic malignancy: performance of T2- and diffusion-weighted MRI with image fusion.
    Nishie A; Stolpen AH; Obuchi M; Kuehn DM; Dagit A; Andresen K
    J Magn Reson Imaging; 2008 Sep; 28(3):705-13. PubMed ID: 18777555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.